Tech Company Financing Transactions
Enterin Funding Round
Enterin closed a $12.7 million Series A funding round on 7/18/2017. Investors included New Ventures and private investors.
Transaction Overview
Company Name
Announced On
7/18/2017
Transaction Type
Venture Equity
Amount
$12,700,000
Round
Series A
Investors
New Ventures (Mark Finn)
Proceeds Purpose
The proceeds from this financing will enable us to complete the ongoing Phase 2 study in PD, further expand our understanding of the role of alpha-synuclein (aS) in the pathology of PD and begin to explore other indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2005 Market St. 3125
Philadelphia, PA 19103
USA
Philadelphia, PA 19103
USA
Phone
Undisclosed
Website
Email Address
Overview
Enterin Inc. is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Zasloff
Chief Medical Officer
Denise Barbut
VP - R & D
William Kinney
Browse more venture capital transactions:
Prev: 7/18/2017: Venus Concept venture capital transaction
Next: 7/18/2017: Awake Security venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs